-5%
Voriconazole, a triazole antifungal, acts by inhibiting fungal ergosterol synthesis. It specifically targets the CYP450-dependent enzyme 14-α-sterol demethylase, leading to reduced ergosterol in the fungal cell membrane, thereby compromising membrane integrity and exerting its antifungal effect.
Voricare is a broad-spectrum triazole antifungal indicated for patients aged 12 years and older for the treatment of:
- Invasive aspergillosis
- Candidemia (in nonneutropenic patients) and deep-seated Candida infections in the skin, abdomen, kidneys, bladder wall, and surgical wounds
- Esophageal candidiasis
- Severe infections caused by Scedosporium apiospermum and Fusarium species, including Fusarium solani
- Patients unresponsive to or intolerant of other antifungal therapies
Use only as directed by a registered physician.